Fig. 1
The effect of PARP inhibitors on cell viability in HRP cancer cells is limited. (A) The effect of olaparib on γH2A.X foci formation in HeLa cells. Hela cells were treated with olaparib at 10 μM for 72 h. Red and blue signals indicate γH2A.X and DAPI (DNA), respectively. Scale bars indicate 50 μ m. (B) (C) The effect of PARP inhibitors on cell viability in HRP OC cells. The HRP OC cell lines were treated with olaparib (B) and niraparib (C) at the indicated concentrations for 72 h. (D) (E) Knockdown efficiencies of siBRCA2 in HeLa cells. Hela cells were treated with siBRCA2 and siNS for 24 h. The knockdown efficiencies were evaluated with qRT-PCR (D) and immunoblotting (E). Cropped immunoblot images are shown. Original blots are presented in Supplementary Fig. 2. (F) (G) Effect of BRCA2 knockdown on sensitivities to the PARP inhibitors in HeLa and SKOV3 cells. HeLa (left) and SKOV3 (right) cells were treated with siNS (black) and siBRCA2 (red), followed by treatment with olaparib (F) and niraparib (G) at the indicated concentrations for 72 h. Data in B–D are shown as means ± SD (n = 3–8).
